

Delisting Notice

CRUCCELL N.V.

DELISTING OF THE SHARES OF COMMON STOCK OF CRUCCELL N.V. FROM THE SIX SWISS EXCHANGE

Company Crucell N.V. (hereinafter "Crucell"), headquartered in Archimedesweg 4-6, 2333CN Leiden (The Netherlands) and incorporated in Leiden, is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. In 2010, Crucell distributed more than 105 million vaccine doses in more than 100 countries around the world. Crucell is one of the major suppliers of vaccines to UNICEF and the developing world. Crucell was the first manufacturer to launch a fully-liquid pentavalent vaccine. They sell vaccines against five important childhood diseases, hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as an oral antityphoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has offices in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, UK, the USA and Vietnam. Crucell employs over 1'300 people.

Shares The Company had 81'742'135 shares of common stock, EUR 0.24 par value, issued and outstanding as of December 6, 2010. The shares of common stock of the Company have a primary listing on NYSE Euronext and a secondary listing on the NASDAQ and on SIX Swiss Exchange (Main Standard).

Delisting The SIX Swiss Exchange has approved the application for delisting of the Company's shares of common stock from the SIX Swiss Exchange. The last trading day will be April 11, 2011 and the delisting will be effective on April 12, 2011.

Crucell intends to delist the shares of common stock from SIX Swiss Exchange simultaneously with the delisting from NYSE Euronext.

Symbol CRX

Valor 1'142'057

ISIN NL0000358562

March, 17 2011

The Company's most recent annual and quarterly reports can be downloaded at <http://www.crucell.com/>. If you have any questions please refer to Frauke Groenevelt, Phone: +31 (0)71 519 7065, Fax: +31 (0)71 519 9800, Email: frauke.groenevelt@crucell.com